Beeline Medicines, a clinical-stage biotechnology company focused on precision therapies for autoimmune and inflammatory diseases, has closed a substantial Series A funding round. The company secured $126.3M to advance its portfolio of therapeutic candidates.
This significant capital infusion, backed by investors including Bain Capital, CPPIB, and BMS, will fuel Beeline's mission to deliver treatments that go straight to the drivers of immune dysfunction. The biotech firm aims to redefine treatment paradigms and transform the lives of people living with these conditions.















